Entering text into the input field will update the search result below

SPRB Spruce Biosciences, Inc.
Stock Price & Overview

$1.500.05 (+3.45%)3:59 PM 12/08/23
NASDAQ | $USD | Post-Market: $1.55 +0.05 (+3.33%) 4:09 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street
Now3M ago6M ago
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered

See SPRB ratings with Premium.

People Also Follow

Company Profile

Spruce Biosciences, Inc. logo
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
  • 611 Gateway Boulevard
  • Suite 740
  • South San Francisco, CA, 94080
  • United States
Phone Number
415 655 4168
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.